Advances in tooth agenesis and tooth regeneration.

The lack of treatment options for congenital (0.1%) and partial (10%) tooth anomalies highlights the need to develop innovative strategies. Over two decades of dedicated research have led to breakthroughs in the treatment of congenital and acquired tooth loss. We revealed that by inactivating USAG-1, congenital tooth agenesis can be successfully ameliorated during early tooth development and that the inactivation promotes late-stage tooth morphogenesis in double knockout mice. Furthermore, Anti- USAG-1 antibody treatment in mice is effective in tooth regeneration and can be a breakthrough in treating tooth anomalies in humans. With approximately 0.1% of the population suffering from congenital tooth agenesis and 10% of children worldwide suffering from partial tooth loss, early diagnosis will improve outcomes and the quality of life of patients. Understanding the role of pathogenic USAG-1 variants, their interacting gene partners, and their protein functions will help develop critical biomarkers. Advances in next-generation sequencing, mass spectrometry, and imaging technologies will assist in developing companion and predictive biomarkers to help identify patients who will benefit from tooth regeneration.

Anti-USAG-1 therapy for tooth regeneration through enhanced BMP signaling.

Uterine sensitization-associated gene-1 (USAG-1) deficiency leads to enhanced bone morphogenetic protein (BMP) signaling, leading to supernumerary teeth formation. Furthermore, antibodies interfering with binding of USAG-1 to BMP, but not lipoprotein receptor-related protein 5/6 (LRP5/6), accelerate tooth development. Since USAG-1 inhibits Wnt and BMP signals, the essential factors for tooth development, via direct binding to BMP and Wnt coreceptor LRP5/6, we hypothesized that USAG-1 plays key regulatory roles in suppressing tooth development. However, the involvement of USAG-1 in various types of congenital tooth agenesis remains unknown. Here, we show that blocking USAG-1 function through USAG-1 knockout or anti-USAG-1 antibody administration relieves congenital tooth agenesis caused by various genetic abnormalities in mice. Our results demonstrate that USAG-1 controls the number of teeth by inhibiting development of potential tooth germs in wild-type or mutant mice missing teeth. Anti-USAG-1 antibody administration is, therefore, a promising approach for tooth regeneration therapy.

Development of a novel polyimide hollow fiber for an intravascular oxygenator.

The authors have synthesized a novel fluorinated polyimide to develop a membrane material for oxygenators and fabricated polyimide hollow fibers for use in an intravascular oxygenator. A dry/wet phase inversion process has been applied to a spinning process to prepare an asymmetric polyimide hollow fiber. The outer surface of the hollow fiber consists of an ultrathin, dense skin layer, with a calculated apparent thickness of approximately 60 nm. The fiber diameter was 800 microns with a wall thickness of 130 microns. The asymmetric hollow fiber has two advantages because (a) the hollow fiber does not produce plasma leakage due to the dense skin layer of the surface and (b) O2 and CO2 transfer rates through the hollow fiber are enhanced due to the ultrathin skin layer and are significantly larger than those of presently available membrane oxygenators. The blood compatibility of the polyimide hollow fiber without heparinization has been evaluated in vitro. Deformation and aggregation of platelets adherent to the fibers were not observed, and the polyimide suppressed platelet activation. The polyimide significantly reduced the production of anaphylatoxin and also suppressed complement activation.

A possible involvement of monoaminergic and opioidergic systems in the analgesia induced by electro-acupuncture in rabbits.

To elucidate mechanisms involved in analgesia induced by effects of electro-acupuncture (EAP), effects of EAP on evoked potentials and release of substance P (SP) following tooth pulp stimulation (ST) in the superficial layers of the trigeminal nucleus caudalis (Vc-I-II) were studied in the rabbit. The potentials evoked by ST were composed of two main components with conduction velocity of ca. 30 m/sec (fast component) and ca. 12 m/sec (late component). The late component was significantly inhibited by morphine (10 mg/kg, i.v.) or CP-96,345 (5 mg/kg, i.v.), an SP antagonist. This inhibitory effect of morphine was antagonized by naloxone (1 mg/kg, i.v.) or methysergide (5 mg/kg, i.v.). In addition, the late component was significantly inhibited by EAP, which was observed in ca. 70% of the rabbits examined. This EAP-induced inhibitory effect was antagonized by naloxone (1 mg/kg, i.v.) or methysergide (5 mg/kg, i.v.), but not by prazosin (5 mg/kg, i.v.) and yohimbine (1 mg/kg, i.v.). The stimulus-evoked SP release was inhibited by EAP, which was significantly antagonized by pretreatment with naloxone (1 mg/kg, i.v.) or methysergide (5 mg/kg, i.v.). These results suggest that one of the mechanisms of analgesia induced by EAP is due to inhibition of the stimulus-evoked SP release in the Vc-I-II through activation of the descending serotonergic systems linking up with opioidergic systems.

Gas transfer and blood compatibility of fluorinated polyimide membranes.

Fluorinated polyimide derived from 2,2'-bis(3,4-dicarboxyphenyl) hexafluoropropane dianhydride (6FDA) and bis[4-(4-aminophenoxy) phenyl]sulfone (APPS) was synthesized to develop a novel membrane oxygenator combining excellent gas transfer and blood compatibility. The asymmetric gas exchange membranes of 6FDA-APPS made by a dry/wet process consisted of an ultrathin and defect-free skin layer supported by a porous substructure. O2 transfer through the 6FDA-APPS membrane was extremely augmented as compared with that of the presently available membrane, poly(dimethylsiloxane), and the previously reported 6FDA-DDS membrane. Since CO2 transfer through the 6FDA-APPS membrane increased with a decrease in CO2 pressure according to dual-mode transport theory, CO2 from the membrane was selectively removed at low CO2 pressure. For the evaluation of in vitro blood compatibility, the platelet adhesion and the plasma protein adsorption on the surface of the 6FDA-APPS membrane were observed by using scanning electron microscopy and the amounts of platelet and plasma protein were determined by an amino acid analyzer. The results indicated that the fluorinated polyimide membranes showed excellent blood compatibility.